| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
|
Medicine details |
|
| Medicine name | atezolizumab (Tecentriq®) |
| Formulation | concentrate for solution for infusion |
| Reference number | 3174 |
| Indication | In combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/07/2019 |
| NICE guidance | |
| Commercial arrangement | PAS |